

# Index

Page numbers in *italics* refer to figures, whilst those in **bold** refer to tables.

- abbreviations, **57**, 57–58
- abdomen, examination of, 225
- abortions, 251
- absorption of drugs
  - in pharmacokinetics, 153–157, *155*
  - in specific patient groups, 240–241, 245–246, 256, 260
- Academy of Medical Royal Colleges, 4
- acceptability, product, 107
- accountability, 40–41, 66–67, 121
- Acts of Parliament, 49
- adherence, 293, 294
- adolescents, 264
- adults, consent from, 65–72
- Adults with Incapacity (Scotland) Act (2000), 74
- Advanced Clinical Practitioners (ACPs), 95
- advance directives, 75, 76, 84
- adventitious breath sounds, **227**
- adverse drug reactions (ADRs), 39, 153, 174–178, 256
- advertising, 109–112
- Advisory Committee on Borderline Substances (ACBS), 60
- advocacy, 75–76, 84
- affinity, 160
- agonists, 160–161, *161*
- aide memoire, 130–131, **131**
- Airedale NHS Trust v Bland*, 85
- alcohol intoxication, 219
- Alert, Verbal, Pain, Unresponsive (AVPU) scale, 219, **219**
- alfacalcidol, 246
- allied health professionals (AHPs), 23–26
  - defined, 2
  - evidence-based practice for, 43
  - explicit consent for, 65
  - in multidisciplinary teams, 190–191
  - prevalence of, 93, 94
  - professional standards for, 39, **40**
  - vital signs for, 207
  - in workforce, 302
- Alzheimer's disease, 75
- ambulatory blood pressure monitoring (ABPM), 216
- aminoglycosides, 231
- anaemia, 214
- antacids, 243
- antagonists, *161*, 161–162
- antibacterials, 8, 210, 251, 290
- antibiotics, 290
- anticholinergic drugs, 243, 257, 291
- antidepressants, 163, 242, 256, 257
- antihistamines, 242, 246
- antihypertensives, 256, 257, 282
- antiparkinsonian drugs, 257
- antipsychotics, 242, 257, 290
- anxiety, 259
- aortic aneurysm, 218
- apex beat, 218
- appendicitis, 221
- appropriate polypharmacy, 288
- arrhythmias, 216
- arteries, 217
- arthritis, 310
- ascites, 241
- aspirin, 231
- assessment(s)
  - holistic, 10–11, 208–209
  - in independent prescribing, 12–14
  - of liver function, 238–239

*The Textbook of Non-medical Prescribing*, Third Edition. Edited by Dilyse Nuttall and Jane Rutt-Howard.  
© 2020 John Wiley & Sons Ltd. Published 2020 by John Wiley & Sons Ltd.  
Companion website: [www.wiley.com/go/nuttall](http://www.wiley.com/go/nuttall)

- assessment(s) (*cont'd*)  
 of mental capacity, 71  
 NEWS2 in, 209–210  
 for PGDs, 27  
 of renal function, 244–245  
 risk, 79–80  
 time for, 98
- 'The assessment of pain in older people'  
 (BPS), 221
- Association of the British Pharmaceutical Industry  
 (ABPI), 109, 111
- asthma, 212, 214, 290, 312–313
- attitudes, about non-medical prescribing, 3–4
- auditory acuity, 231
- auroscopes, 230–231
- auscultation, 226, 227
- automated blood pressure monitors, 215–216,  
**217**
- autonomy, 61–64  
 and accountability, 41  
 and informed consent, 67–69  
 respect for, 82–83  
 for young people/children, 72, 74
- Battle's sign, 219
- Bayesian theory, 142
- beneficence, 83
- benzodiazepines, 246, 256
- 'best interest' principle and decision, 72, 74, 75, 84
- beta-adrenoceptors, 257
- $\beta$  blockers, 154
- biases, in CDM, 147
- bioavailability, 156–157, 240–241, 245–246
- biological medicines, 164, 166
- biomechanics, 193
- biosimilars, 166
- Black Report, 9
- blood clotting, 241–242, **242**
- blood pressure (BP), 154, 172, 211, 215–217, **216**
- body language, 121, 123, **124**, 209
- body surface area (BSA), 261
- body systems, examination of, 228–231
- body water, 157
- Bolam v Friern Hospital Management  
 Committee*, 52
- borderline substances, 61
- Botox®, 9, 46
- brachial artery, 218
- bradypnoea, 213
- breastfeeding mothers, 253–255, **255**
- breast milk, 253–254
- breathing, assessment of, 212–215
- breath sounds, 226, **227**
- Brexit, 302
- British and Irish Hypertension Society (BIHS),  
 215, 216
- British Medical Association (BMA), 66, 72, 74, 75,  
 81, 111
- British National Formulary* (BNF), 19, 55, 60  
 on drugs for breastfeeding mothers, 254, 255  
 on drugs for patients with liver  
 impairment, 240  
 on drug suitability in pregnancy, 250–252  
 and IMPACT tool, 290  
 and influence of product on prescribing, 107  
 liver disease in, 157  
 in medicines reconciliation, 293  
 on renal impairment, 245  
 used in pharmacology, 169–170
- British National Formulary for Children (BNFC),  
 107, 260–262
- British Pain Society (BPS), 221
- bromocriptine, 255
- calcitriol, 246
- calcium channels, 242, 289
- calcium resonium, 246
- Caldicott guardians, 77
- cancer, 222, 258, 266, 267
- cannabis, reclassification of, 296
- cardiovascular disease, 258
- care, 7, 51–53
- Care Quality Commission (CQC), 60
- care settings, information sharing between,  
 291–292
- carotid artery, 218
- carrier molecules, 163
- case law, 48
- case studies, 309–320  
 health professional, 315–320  
 patient, 309–314
- Centor criteria, 220
- Chartered Society of Physiotherapy (CSP), 42, 191
- Chatterton v Gerson*, 67
- chemical drug interactions, 172
- chemotherapy, 83
- Chester v Afshar*, 52, 68
- children, 260–266, **266**  
 advocacy for, 75  
 assessing pain for, 222  
 case studies, 312–313  
 consent from, 68, 72–74  
 considerations with prescribing for, 263  
 consultations with, 126, **127**

- defining, 260
- dosing for, 261
- excipients for, 262
- holistic approach to prescribing for, 264–265
- licensing of medicines for, 261–262
- pharmacokinetics for, 260–261
- professional responsibilities related to prescribing for, 263–264
- treated by podiatrists, 193
- Children Act (1989), 73, 265
- Children Act (2004), 265
- chiropractors, 24–25
- chronic illness, 268, 293
- chronic kidney disease (CKD), 245, 246
- chronic respiratory disease, 215
- civil law, 50, 50, 51
- clinical algorithms, 142
- clinical commissioning group (CCG), 290–291, 317
- clinical decision-making (CDM)
  - cognitive continuum in, 142
  - in consultation models, 129, 141–147
  - difficulties in, 118
  - dynamism of, 146–147
  - heuristics as strategy for, 145–146
  - hypothetical–deductive model for, 142–143
  - intuition as strategy for, 145–146
  - involving patients in, 120
  - pattern recognition in, 143–144
  - therapeutic communication and, 121
- clinical environment, 224, 278
- clinical examination, 222–228
  - anatomy and physiology, 228
  - auscultation, 226, 227
  - ear, nose, and throat examination, 230–231
  - implied consent to, 65
  - inspection, 224–225
  - palpation, 225
  - percussion, 225–226
  - principles, 223–224
  - red flags, 228
  - of respiratory system, 228, **229–230**
- clinical management plan (CMP), **15**, 15–18, **16**, 66, 312–313
- clinical practice, 6
- clinical presentation, 131
- clinical reasoning, 143
- clinical skills, 207–235
  - clinical examination, 222–228
  - examination of body systems, 228–231
  - holistic assessment, 208–209
  - National Early Warning Score, 209–211
  - vital signs, 211–222
- cocaine, 21, 23
- codeine, 24, 246
- Code of Practice for the Pharmaceutical Industry, 109
- cognitive continuum, 142
- collaboration, 185, 201, 302
- College of Paramedics, 42
- commissioners, 198–199
- commitment, 7
- common law, 50
- communication, 7. *see also* therapeutic communication
  - with children/young people, 264–265
  - in clinical examination, 223
  - in consultation, 101
  - email, 121
  - in media, 112
  - in multidisciplinary teams, 113, 197, 199–200
  - non-verbal, 121, 123
  - with older people, 258
  - paralinguistic features of, 121, **122**, 123
  - in patient's language, 104–105, 268
  - on unlicensed/off-label medicines, 60–61
  - verbal, 121, 123
- community care, 302
- community children's health nurses, 19
- community matrons, 120
- community mental health nurses, 19, 20
- community pharmacists, 317
- Community Practitioner Nurse Prescriber Formulary*, 19
- community practitioner nurse prescribers, 47, 167
- Community Practitioner Nurse Prescribing (CPNP) programme, 319
- community practitioner nurses, xvii, 19–21
- community staff nurses, 316
- co-morbidities, 170–171, 175–176, 179, 255, 311
- comparative needs, 10
- compassion, 7
- Compassion in Practice* (NHS Commissioning Board), 7
- competence, 7, 86
  - with children and young people, 263–264
  - with clinical skills, 207, 208, 235
  - and consultation umbrella model, 148
  - to enhance non-medical prescribing, 303
  - and group-specific prescribing, 269
  - in history taking, 130
  - and influences on prescribing, 114
  - in multidisciplinary teams, 203–204

- competence (*cont'd*)  
 in pharmacology, 180–181  
 of practitioners, 118, 190  
 in United Kingdom, 30
- A Competency Framework for all Prescribers (RPS)*,  
 xix–xxi, 3, 6, 37
- on autonomy, 62  
 on collaboration, 185  
 Consultation domain, xix–xx, 39, 40, **276**  
 on consultations, 117  
 on evidence-based practice, 280  
 and future of non-medical prescribing, 300  
 and independent prescribing, 13  
 prescribing for children in, 263–264  
 Prescribing Governance domain, xx–xxi, 39,  
 40, **276**  
 and reflective practice, 276, 278  
 on shared decision-making, 76  
 and 6 Cs, 7  
 on standards of prescribing, 190  
 on unlicensed/off-label medicines, 60  
 V300 status in, 21
- complementary medications, 292
- compliance, 65, 140, 255, 293
- conclusion, of consultation, 141
- concordance, 11, 140, 259, 293–296, **294**
- confidence, 102, 108, 118
- confidentiality, 76–79, **78**, 186, 265  
*Confidentiality Policy* (NHS England), 76
- consciousness level, 219, 224
- consent, 64–76  
 for adults lacking mental capacity, 70–72  
 from adults with mental capacity, 65–69  
 in advance directives, 75  
 from children, 72–74  
 to clinical examination, 211  
 importance of, 64–65  
 informed, 66–69  
 for inspection, 224  
 in lasting power of attorney, 74  
 and prescribers as advocates, 75–76  
 and respect for autonomy, 83  
 from young people, 72
- consequentialism, 81–82
- constipation, 242–243, 289, 291
- consultation(s)  
 with children, **127**  
 models for, 120, 126, 128–130  
 patient's experience of, 101  
 time for, 98
- Consultation domain, xix–xx, 39, 40, **276**, 278
- consultation umbrella model, 117–148, 119  
 about, 118–119  
 clinical decision-making in, 141–147  
 conclusion, 141  
 and consultation models in context, 126–130  
 follow-up, 140–141  
 history taking, 130–138  
 physical examination, 138–139  
 plan/treatment, 139–140  
 tests and investigations, 139  
 therapeutic communication in, 119–126
- consumers, patients as, 103
- contact professional of MDPT, 200
- continuing professional development (CPD), xxi  
 building numeracy skills, 299  
 clinical skills and, 235  
 and consultation umbrella model, 148  
 enhancing NMP through, 296–299, 303  
 funding for, 96  
 future of, 300–303  
 and group-specific prescribing, 269  
 influence of, on prescribing, 100, 114  
 in MDPTs, 187, 203–204  
 for nurses and midwives, 190  
 personal development plan for, 298  
 in pharmacology, 180–181  
 professional, legal and ethical issues related  
 to, 86  
 reflective practice and, 276, 279  
 in United Kingdom, 30
- contraception, 251
- controlled drugs  
 independent prescribing of, xviii  
 legal issues, 58–60  
 prescriber's access to, 21, 23–26, **54**  
 supplementary prescribing of, 18  
 transcribing and, 47
- Controlled drugs* (NICE), 60
- corticosteroids, 290
- cost-effectiveness, 7, 107, 108, 301
- courage, 7
- creatinine clearance (CrCl), 244, 245
- credentials, 102
- criminal behaviour, 42, 44–45
- criminal law, 50, 50–51
- The Crown Report* (DH), xvii
- The Crown Report II* (DH), xvii–xviii, 3, **3**
- cuff size, blood pressure, 215
- cultural competence, 103–105
- culture, national, 103–105, 267–268. *see also*  
 social and cultural issues
- culture, organisational, 97–98
- Cumberlege, Julia, 93

- Cumberlege Report, xvii  
 cytochrome P450 enzymes, 158, **159**
- Daclizumab, 243  
 data protection, 77–79, **78**  
 Data Protection Act, revised (2018), 77  
 death, doctrine of double effect and, 84–85  
 dementia, 75, 258, 259, 290  
 deontology, 67, 82  
 Department of Health (DH). *see also specific publications*  
   access to healthcare as goal of, 98  
   on collaboration, 201  
   on confidentiality, 77  
   on consent, 64, 70–71  
   on definition of tort, 51  
   on health of gypsies and travellers, 268  
   on independent prescribing, 11–12, 24  
   and MHRA, 38  
   on non-medical prescribing in private sector, 8–9  
   and pharmaceutical companies, 109  
   on supplementary prescribing, 14, 18, 24  
   on whistleblowing, 44  
 Department of Health, Social Services and Public Safety Northern Ireland, 244  
 Department of Health Social Security, xvii  
 dependent prescribing, 14  
 deprescribing, 288  
 depression, 244, 259, 311  
 Designated Medical Practitioner (DMP), 231, 300  
 determinants of health model, 278  
 diabetes, 267, 309  
 diagnosis, 13, 18, 130, 143, 240  
 diagnostic radiographers, 192, 320  
 diamorphine, 21, 23  
 diaphragm, 226  
 diastolic pressure, 215  
 diazepam, 24  
 diethylstilboestrol, 249  
 dietitians, xviii, 17, 24, 194  
 digital learning, 297  
 digoxin, 179, 256, 257  
 dihydrocodeine, 24  
 dipipanone, 21, 23  
 directly acting oral anticoagulants (DOACs), 244  
 Disability Discrimination Act (2005), 62  
 discrimination, 83  
 disease state, adverse drug reactions and, 176  
 disposal of medicines, 258  
 distribution of drugs  
   in pharmacokinetics, 157–158  
   in specific patient groups, 241, 246, 256, 260  
 district nurses (DN), xvii, xviii, 1, 19, 195, 302  
 diuretics, 257  
 doctor, role of, 4. *see also* general practitioners (GPs)  
 documentation, 99  
*Donoghue v Stevenson*, 61  
 dosage, 156, 247, 258, 261  
 double effect, doctrine of, 84–85  
 dress, in clinical examination, 209, 224  
 drug action, targets for, **165–166**  
 drug dependency, 64  
 drug-induced liver disease, 243  
 drug interactions, 158, 169, 172–173, 179  
 drug safety profile, 254  
 drugs and therapeutics committees, 39  
 Drug Tariff Resource Centre, 61  
 DSFDQN mnemonic, 57, 59  
 duloxetine, 168–169  
 duty of care, 51–53  
 dyspnoea, 213  
 Dysport®, 46
- ear, nose, and throat (ENT) examination, 208, 230–234  
   auroscope technique, 230–231  
   ear examination, **232**  
   mouth examination, **233**  
   neck examination, **233**  
   nose and sinus examination, **232–233**
- economic context, for NMP, 7–8, 274  
 education and educational programmes, 28, 36, 169, **188**, 201, 300–303  
 ego-states, 128  
 Electronic Medicines Compendium, 252, 255  
 electronic patient medical notes, 99  
 electronic prescriptions, 58, 99  
 elimination, of drugs, 241, 246  
 email communication, 121  
 emergency supply requests, 61  
 emotions, in consultation, 102  
 employment contracts, 42–43  
 end-of-life care, 76, 84–85  
 England, 35, 72, 74, 251, 267  
 enzymes, 158, **159**, 164  
 errors, 4, 44, 47, 79–80, 189, 199, 283  
 Esmya, 243  
 estimated glomerular filtration rate (eGFR), 244–245  
 ethical principles, 82–83  
 ethical theories, 81–82  
 ethics, 80–86  
   best interest principle, 84  
   changes in, 35–36

- ethics (*cont'd*)  
 doctrine of double effect, 84–85  
 respect for persons, 83
- ethnic minority groups, 103, 176, **267**,  
 267–268
- European Convention of Human Rights and  
 Biomedicine (1997), 67–68
- evidence-based practice, 43–44, 107, 280–282,  
 284, 297
- excipients, 262, **262**
- excretion of drugs  
 in breast milk, 253–254  
 for children and young people, 261  
 for older people, 256  
 and pharmacokinetics, 159–160
- expectations, of patients, 10–11, 101–102
- explicit (express) consent, 65, 66
- expressed needs, 10
- extended formulary prescribing, xviii
- external influences on prescribing, 109–113
- eye contact, 209
- FACECARES mnemonic, 294, **294**
- facial expressions, 209, 224
- fall prevention, 259
- Family Law Reform Act (1969), 72–74
- family members, 76, 198–199. *see also* parents
- fatalism, 106
- felt needs, 10
- fentanyl, 24
- fever, 220
- Fifth Report, 44
- first-pass metabolism, 157, 240–241
- 5HT3 antagonists, 242
- follow-up, 140–141
- formularies  
 building and developing, 167–169  
 defined, 108  
 and product influence on prescribing,  
 107–109  
 regional, 301  
 for V100 prescribers, 19
- formulary committees, 295
- four As for patient outcomes, 222
- Fourth Report, 44
- Francis, Sir Robert, 36, 44–45
- Francis Report, 7, 36
- Fraser competency guidelines, 73
- fraud, 44–45
- funding, 96–97, 301
- furosemide, 231
- 'Future Nurse' (NMC), 187
- $\gamma$ -aminobutyric acid (GABA), 162
- gastrointestinal (GI) tract, 156
- gender differences, in ADRs, 176
- General Data Protection Regulations (GDPR), 77
- General Medical Council (GMC), 45, 46, 65, 66, 105
- General Optical Council (GOC), 26, 28, 192
- General Pharmaceutical Council (GPhC), 22, 28,  
 36, 40, 65, 68–69, 188, 300
- general practice nurses, 19
- general practitioners (GPs), 47, 99, 188, 208,  
 291–292
- general sales list (GSL) medicines, 38
- gentamicin, 241, 246, 256
- Gillick competency guidelines, 73
- Gillick v West Norfolk and Wisbech Area Health  
 Authority*, 73
- Glasgow Coma Scale (GCS), 219, **219**
- gloves, using, 211
- 'good' prescribing, 282, 283
- governance  
 Prescribing Governance domain, xx–xxi, 39,  
 40, 278  
 in private sector practices, 8–9
- government policy, 302
- grooming, in clinical examination, 209
- group ethics, 81
- group-specific prescribing, 238–269  
 breastfeeding parents, 253–255  
 children and young people, 260–266  
 gypsies and travelling families, 268–269  
 members of ethnic minority groups, 267–268  
 men, 266–267  
 older people, 255–259  
 patients with liver disease, 238–244  
 patients with renal impairment, 244–248  
 pregnant women, 248–252
- guiding framework for prescribing, **37**
- gypsies, 268–269
- half-life, of drugs, 159–160, **160**
- hand hygiene, 210, 210–211
- hands, inspection of, 225
- harm, 79–80
- Health and Care Professions Council (HCPC), 23,  
 24, 28, 40, 69, 194
- health belief model, 105–106
- health beliefs, 105–106, 268
- Health Care and Associated Professions  
 (Indemnity Arrangements) Order (2014),  
 41–42
- healthcare associated infections, 210
- healthcare settings, 128, 140

- Health Education England (HEE), 4, 95
- health professionals
- case studies of, 315–320
  - in MDPTs, 195
  - medicines optimisation for, 286
  - NMP for, 2, 6, 11–26, **299**
  - in workforce, 302
- Health Professions Council (HPC), 191, 193
- health risks, ethnicity-specific, 267
- health services
- access to, 267, 268
  - structures in, 187
- health status, **208**, 208–209
- Health Survey for England, 267
- health visitors (HV), xvii, xviii, 1, 19, 21–22, 315
- heparin, 249, 254
- hepatic encephalopathy, 242
- heuristics, 145–146
- history taking, **131**, **132–138**
- with children/young people, 264
  - for clinical examination, 223
  - in clinical examination, 224–225
  - in consultation umbrella model, 130–138
  - influence of, on prescribing, 101
- holistic approach to prescribing
- for breastfeeding mothers, 254–255
  - for children/young people, 264–265
  - with liver disease/impairment, 243–244
  - by MDPTs, 195
  - for older people, 258–259
  - for pregnant women, 251–252
  - with renal impairment, 247–248
- holistic assessment, 10–11, 208–209
- home blood pressure monitoring (HBPM), 216
- hospitals, 283, 291–292. *see also* secondary care
- Human Medicines Regulations (2012), 37, 110, 296
- Human Medicines (Amendment) Regulations (2018), 37–38
- Human Rights Act (1998), 67
- hyperpolypharmacy, 288
- hypertension, 215–217
- hypnotics, 242, 257, 290
- hypoglycaemia, 219
- hypotension, 215
- hypothermia, 220
- hypothetical–deductive model, 142–143
- immunisation, 27, 258
- IMPACT (Improving Medicines and Polypharmacy Appropriateness Clinical Tool) project, 290–291
- implied consent, 65
- incapacitated adults, 74
- indapamide, 168, 171
- indemnity insurance, 41–42
- independent prescribers and prescribing, xviii, 13–14
- by allied health professionals, 24–26, 190–191
  - assessment in, 12–14
  - case studies, 317–319
  - clinical examinations by, 208
  - in clinical practice, 6
  - consent for, 66
  - for diagnosed/undiagnosed conditions, 13
  - by nurses, 21–22, 189
  - by optometrists, 193
  - by pharmacists, 23, 189
  - prescribing decision for, 13
  - supplementary prescribers and, 14–15
  - in United Kingdom, 11–14
- infants, 254, 264, 312
- infant formula, 253
- influences on prescribing, 93–114
- external, 109–113
  - media, 112
  - in multidisciplinary teams, 112–113
  - patient, 101–107
  - pharmaceutical companies, 109–111
  - prescriber, 93–100
  - product, 107–109
- information
- about drugs for pregnant women, 250–251
  - Internet as source of, 112, 281
  - sharing, 67–69, 77–79, **78**, 186–187, 291–292
- Information Commissioner's Office (ICO), 78
- inhaled corticosteroids, 290
- initial impression of health status, **208**, 208–209
- injectable medicines, 9, 46
- In Re E, 73
- inspection, 224–225
- institutional factors, in prescribing, 96–98
- insulin, 246, 249, 254
- integrity, 83
- International Dysphagia Diet Standardisation Initiative (IDDSI) framework, 296
- Internet, health information from, 112, 281
- interprofessional, 184
- intonation, 121
- intramuscular injections, 260
- intuition, 145–146
- investigations, 139
- ion channels, 162–163

- ionised drugs, 254  
 ischaemic sudden death, 266
- joint decision making, 62  
 joint vicarious liability, 43  
 justice, principle of, 83
- Kant, Immanuel, 63, 69, 82  
 knowledge, 95, 110–111
- lactation, drug-induced reduction in, 255  
 language, communicating in patients',  
 104–105, 268  
 Lasting Power of Attorney (LPA), 70, 74, 84  
 Latin abbreviations, **57**, 57–58  
 Law Society, 75  
*Leading Change, Adding Value* (NHS England), 7  
 learning, in reflective practice, 279  
 learning difficulties, patients with, 311  
 legal issues and legislation, **37**, 48–80, 86  
   autonomy, 61–64  
   changes in, 35–36, 296  
   confidentiality, information sharing and data  
   protection, 76–79  
   consent, 64–76  
   doctrine of double effect, 84–85  
   harm, risk assessment, avoiding errors and  
   litigation, 79–80  
   making clinical examination as, 208  
   medicines legislation, 37–39  
   negligence and duty of care, 51–53  
   prescription writing, 53–58  
   and regulatory framework, 36–37  
   special types of drugs and requests, 58–61  
   UK legal system, 48–51  
 liability, vicarious, 42–43  
 liberty and security, right to, 67  
 licensing medicines, 261–262  
 life, sanctity of, 85  
 ligands, 160, 162  
 lipid-soluble drugs, 254, 256  
*Lister and ors v Hesley Hall Ltd*, 43  
 lithium, 172, 179, 256, 287  
 litigation, avoiding, 79–80  
 liver disease or impairment, 170, 238–244, **244**  
   and adverse drug reactions, 175  
   diagnosis of, 240  
   drug induced, 243  
   holistic approach to prescribing and, 243–244  
   liver function tests, 239  
   pharmacology in, 240–243  
   signs/symptoms of, 239, **239**
- liver function, 157, 158, 238–239, 256  
 liver function tests (LFTs), 239, **239**  
 living wills, 75  
 local formularies, 7–8, 107–108, 295  
 locus of control theory, 105, 106  
 log-term conditions  
   pregnant women with, 250  
 lone workers, 96  
 long-term conditions  
   breastfeeding mothers with, 253  
   medication waste associated with, 283  
   older people with, 126  
   pattern recognition in patients with, 144  
   psychological needs of patients with, 244  
   supplementary prescribing for, 17–18  
 loperamide, 243  
 lorazepam, 24, 25  
 lower limbs, pulses in, 217  
 lungs, auscultation of, 226  
 lymph glands, examination of, **234**
- Making Amends, 52  
*Making the Connections* (DH), 3  
 malabsorption syndromes, 256  
 Management of Controlled Drugs in Care  
   Homes, 60  
 manual blood pressure monitoring, **216**  
 marketing authorisation (MA), 261  
 maternal factors, in drug concentration in  
   breastmilk, 253–254  
 media, 112  
 Medical Defence Union (MDU), 42, 80  
 Medical Devices Agency (MDA), 39  
 medical equipment, 211  
 medical ethics, 81  
 medical gloves, using, 211  
 medical prescribing, 5  
 medical records, 18, 125, 130–131  
 medication reviews, 258, 286–288, 290–291  
 Medicines Act (1968), 38, **38**, 53  
 Medicines Act (1992), 1–2  
*Medicines adherence* (NICE), 62  
 Medicines and Healthcare Products Regulatory  
   Agency (MHRA), 9, 27, 38–39, 46, 60, 109,  
   110, 156, 166, 243, 263, 284  
 Medicines and Older People, 255  
 Medicines Control Agency (MCA), 39, 111  
 Medicines Information Centre, 261  
 medicines legislation, 37–39  
 medicines management, 282–296  
   activities of, 296  
   building concordance with, 293–296



- medication review for, 286–288
  - medicines reconciliation, 292–293
    - with polypharmacy, 288–291
    - at primary/secondary care interface, 291–292
    - as priority, 282–283
  - medicines management boards, 295
  - Medicines Matters* (DH), 3
  - medicines optimisation, 8, 283–288, 295
  - medicines reconciliation, 292–293
  - men, 251–252, 266–267
  - mental capacity, 65–72, 74
  - Mental Capacity Act (2005), 70, 71, 74, 84
  - Mental Health Act (2007), 48
  - mental health issues, 264, 268. *see also specific conditions*
  - mentoring, 96, 97
  - metabolism of drugs
    - in pharmacokinetics, 158–159
    - for specific patient groups, 246, 256, 260–261
  - methotrexate, 287
  - Mid Staffordshire NHS Foundation Trust, 36
  - midwives
    - case studies, 316
    - in MDPTs, 189–190
    - prescriptions for pregnant women from, 250–251
    - supplementary prescribing by, 17
    - V300 status for, 21, 22
    - in workforce, 302
  - migrants, 104
  - Mill, John Stuart, 82
  - Misuse of Drugs Act (1971), 37, 38, 58, 59, 296
  - Misuse of Drugs Regulations (2001), 59
  - Modernising Nursing Careers* (DH), 187
  - moral rules, 48
  - morphine, 24
  - mothers, breastfeeding, 253–255, **255**
  - mouth, examination of, **233**
  - Ms B v An NHS Trust*, 70
  - multidisciplinary prescribing teams (MDPTs), 183–204, **196**
    - benefits, 185, 196–198
    - case studies, 318
    - commissioning, 198–199
    - defining, 183–184
    - drivers for, 184–185
    - education/learning on, 201
    - medicines optimisation for, 284
    - model for working practice, 185–187
    - organisation of, **186**
    - patient involvement in, 281
    - prescribing as consideration in, 188
    - problems with, 199–200
    - in reflective practice, 278
    - relationships within, 98, 112–113
    - team member roles, 188–196
  - multiple drug therapy, 175–176
  - multiprofessional, defined, 184
  - musculoskeletal examination, 223
  
  - narcotic medication, 213
  - National Co-ordinating Centre for NHS Service Delivery and Organisation (NCCSDO), 293
  - National Early Warning Score (NEWS), 209–211
  - National Health Service (NHS). *see also entries beginning NHS*
    - accountability to, 40, 41
    - economic context for prescribing, 7–8
    - funding from, 96
    - information gathering by, 77
    - medication spending by, 109
    - medicines management for, 282, 283
    - non-medical prescribers as resource for, 274, 275
    - PGDs definition, 26
    - and PrescQIPP, 290–291
    - and private sector, 8
    - redress for negligence claims by, 52–53
    - whistleblowing at, 44
    - workforce of, 302
  - National Institute for Health and Clinical Excellence (NICE), 60
    - on changes at interface of care, 291, 292
  - children as defined by, 260
  - on collaboration, 104
  - and *Competency Framework for all Prescribers*, 300
  - on concordance, 294
  - on ethnic minority populations, 267–268
  - hypertension defined by, 215
  - on liver disease or impairment, 244
  - on medication reviews, 287
  - on medicines optimisation, 284–285
  - on medicines reconciliation, 292
  - on paternalism, 62
  - on product choice, 107
  - on renal disease, 245
  - on risk management, 80
- National Prescribing Centre (NPC), xix, 3
  - National Service Frameworks (NSF) for Older People, 255
  - National Teratology Information Service, 251
  - neck, examination of, **234**

- negligence, 42, 51–53
- negotiation, in plan or treatment, 139–140
- Neighbour's Inner Consultation, 129
- neonates, 254, 260
- nephrotoxicity, 246–247
- neuroleptics, 256
- NEWS2, **209**, 209–212, 215
- NHS Business Services Authority, 47
- NHS Choice, 281
- NHS Commissioning Board, 7
- NHS Counter Fraud Authority, 47
- NHS England, 6, 7, 41, 45, 76, 103, 244, 258, 299
- NHS Improvement, 45, 301
- NHS Redress Act (2006), 53
- NHS Redress Bill (2005), 52
- NHS Redress Scheme, 53
- NHS Scotland, 289
- NHS Security Management Service, 47
- NHS Specialist Pharmacy Service, 289–290
- nicotine, 160–161
- non-compliance, patient, 293
- non-maleficence, 83
- non-medical prescribers, defined, 2. *see also specific types*
- non-medical prescribing (NMP). *see also specific topics*
- attitudes about, 3–4
  - benefits, 94
  - defining, 2
  - future of, 299–303
  - medical prescribing vs., 5
  - in multidisciplinary teams, 188
  - prevalence of, 93–94
  - role of, 6
  - success with, 274–275
  - vision for, 3
- non-medical prescribing lead, 195, 198–199
- non-steroidal anti-inflammatory drugs (NSAIDs), 231, 246, 257, 287, 291
- non-verbal communication, 121, 123
- non-verbal consent, 65
- noradrenaline (NA), 163
- normative needs, 10
- Northern Ireland, 35, 72, 74
- nose, examination of, **232–233**
- NO TEARS tool, 289
- numeracy skills, 299
- nurse prescriber formulary (NPF), xvii, xviii
- nurse prescribing and prescribers, 2
- attitudes about, 4
  - development of, xvii–xviii
  - explicit consent for, 65
  - history of, 1–2
  - influences on prescribing by, 96–97
  - in MDPTs, 189–190, 197
  - prevalence of, 93, 94, 299–300
  - professional standards for, 39, **40**
  - supplementary prescribing by, 17
  - types of, 19–22
  - vital signs for, 207
  - in workforce, 302
- Nurse Prescribing Bulletin* (NPC), 3
- Nursing and Midwifery Council (NMC), xviii, 2, 9, 19, 21, 28, 40, 45–47, 69, 96, 97, 100, 187, 190, 263, 300, 301
- nutritionists, 194
- oestrogens, 255
- off-label medicines, 60–61, 261–262
- older people, 255–259, **259**
- adverse drug reactions of, 176
  - case studies, 314
  - co-morbidity and polypharmacy for, 171
  - considerations with prescribing for, 258
  - consultations with, 126
  - drugs to be used with caution, 257
  - holistic approach to prescribing to, 258–259
  - pharmacodynamics for, 257
  - pharmacokinetics for, 256
  - STOPP/START screening tool for, 289
- oligopharmacy, 288
- opiates, 85
- opioids, 242, 257, 290
- Optical Council, 60
- optometrists, xviii, 17, 26, 60, 192–193, 319
- oral administration, 156, 260
- oral temperature, 220
- organisation(s), 97–99, **141**, 286
- organisational culture, 97–98
- orthopnoea, 213
- orthostatic hypotension, 215
- otalgia, 230
- Outcomes Framework* (NHS England), 6
- over-the-counter medications, 103, 292, 301
- Owers v Medway NHS Foundation Trust*, 52
- oxycodone, 24
- oxygen saturation, 214–215
- PACT (Prescribing Analysis and CosT) data, 275
- pain, 212, 220–222
- pain relief ladder, 222
- pain scales, 221–222
- palpation, 217, 225
- paracetamol, 174, 290

- paralinguistic features of communication, 121, **122**, 123
- paramedics, xviii, 25–26, 194, 296, 302, 320
- parents
  - breastfeeding mothers, 253–255, **255**
  - and prescribing for children, 72–73, 264, 265
- paroxysmal nocturnal dyspnoea (PND), 213
- partnership, in supplementary prescribing, 14–15
- paternalism, 61–62
- patient(s)
  - attitudes about NMP of, 4
  - autonomy, 61–64
  - benefits of MDPTs for, 198
  - building concordance with, 293–296
  - case studies of, 309–314
  - consent from, 64–76
  - consultation for, 101
  - as consumers, 103
  - cultural issues for, 103–105
  - decision-making with, 120, 139–140
  - in evidence-based practice, 281
  - health beliefs of, 105–106
  - influence of, on prescribing, 101–107
  - on MDPTs, 195
  - medication reviews with, 286–288
  - medicines management by, 282–296
  - medicines optimisation for, 285
  - needs/expectations of, 10–11, 101–102
  - in reflective practice, 278
  - relationship building with, 123, 125
  - in supplementary prescribing partnership, 15
- patient care, pharmacology and, 153–154
- patient-centred approach, 105, 106, 288–289, 289
- patient decision aids, 283
- patient experience, 283–284
- patient group directions (PGDs), 24, 26–28, 38, 53
- patient groups, 285, 287. *see also* group-specific prescribing
- Patient Safety Alert, 296
- patient-specific directions, 27–28
- pattern recognition, 143–144
- peak expiratory flow rate (PEFR), 213–214
- peak flow, **213**, 213–214
- peer support, 96–97
- percussion, 225–226, **226**
- personal characteristics, of prescribers, 95
- personal development plans, 298
- personal ethics, 81
- pethidine, 242
- pH, of breast milk, 254
- pharmaceutical companies, 109–111, 185, 200
- Pharmaceutical Society of Northern Ireland (PSNI), 43
- pharmacists and pharmacist prescribers, 2
  - attitudes about, 4
  - case studies, 317
  - development of prescribing for, xviii
  - explicit consent for, 65
  - independent prescribing by, 23
  - influences on prescribing by, 95, 96
  - in MDPTs, 188–189, 197
  - prevalence of, 93–94
  - professional standards for, 39, **40**
  - supplementary prescribing by, 17, 22–23
  - taking of vital signs by, 207
  - transcribing by, 47
- Pharmacists' Defence Association (PDA), 42
- pharmacodynamics, 160–166
  - biological medicines, 164, 166
  - biosimilars, 166
  - carrier molecules, 163
  - drug interactions, 172
  - enzymes, 164
  - ion channels, 162–163
  - in liver disease or impairment, 241–243
  - for older people, 257
  - and patient care, 154
  - receptors, 160–162
  - in renal impairment, 246–247
- pharmacokinetics, 155–160
  - absorption, 155–157
  - for children and young people, 260–261
  - distribution, 157–158
  - drug interactions, 172
  - excretion, 159–160
  - with liver disease or impairment, 240–241
  - metabolism, 158–159
  - for older people, 256
  - and patient care, 153–154
  - in pregnancy, 249, **249**
  - with renal impairment, 245–246
- pharmacology, 152–181
  - adverse drug reactions, 174–178
  - BNF use, 169–170, 293
  - building/developing formularies, 167–169
  - co-morbidities, 170–171
  - drug interactions, 172–173
  - drugs with narrow therapeutic index, 178–179
  - introduction to, 154–166
  - in liver disease/impairment, 240–243
  - as part of prescribing process, 153
  - and patient care, 153–154
  - resources, 180

- pharmacovigilance, 103, 177  
 pharmacy (P) medicines, 38  
 phenobarbital sodium, 59  
 phenothiazine, 257  
 phenytoin, 178, 241  
 philosophical ethics, 81  
 phosphate binders, 246  
 photodermatitis, 60  
 physical drug interactions, 172  
 physical examination, 138–139, **223**. *see also*  
     clinical examination  
 physiotherapists, xviii, 17, 18, 24–25, 191, 318  
 plan (or treatment), 120, 139–140  
 planned behaviour, theory of, 105, 106  
 plasma proteins, 241  
 pneumonia, 221  
 podiatrists, xviii, 17, 18, 24–25, 193–194, 319  
 podopaediatrics, 193  
 political environment, 279  
 polypharmacy, 288–291  
     and adverse drug reactions, 175–176  
     case studies, 310, 311  
     and co-morbidity, 170–171  
     and medication review, 288–289, 289  
     for older people, 258  
 post-surgical care, 312  
 postural hypotension, 215  
 PQRST mnemonic, 221  
 practice assessors, 300, 301  
 practitioners, use of term, 117  
 prednisolone, 212, 241  
 pregnant women, 248–252, **249**, 310  
 premature infants, 254  
 pre-pregnancy counselling, 250  
 pre-registration training, 36  
 PrescQIPP, 290–291  
 prescribers, 11–26. *see also specific types*  
     as advocates, 75–76  
     benefits of MDPTs for, 197  
     feelings of vulnerability of, 96  
     independent, 11–14  
     influence of, on prescribing, 93–100  
     institutional/resource factors for, 96–98  
     permissions for, **299**  
     personal characteristics of, 95  
     prescribing rights of, 53–55, **54**  
     professional issues for, 100  
     in reflective practice, 278  
     role/responsibility changes, 96–97  
     supplementary, 14–19  
 prescribing. *see also specific types, e.g.:* independ-  
     ent prescribing  
     as consideration of MDPTs, 188  
     development of, xvii–xviii  
     evolution in, 1–2  
     influences on, *see* influences on prescribing  
     other healthcare practices vs., 5  
     PGD use vs., 26–28  
     pressures and responses in, 28–29, 29  
     regulatory framework for, 36–37  
     safety in, 5  
     transposing/transcribing vs., 46–47  
 prescribing agreements, 97  
 prescribing competencies, xix–xxi  
     clinical skills and, 235  
     and consultation umbrella model, 148  
     enhancing NMP and, 303  
     and group-specific prescribing, 269  
     and influences on prescribing, 114  
     for MDPTs, 203  
     in pharmacology, 180  
     professional, legal and ethical issues with, 86  
     in United Kingdom, 30  
 prescribing decision, 13  
 Prescribing Governance domain, xx–xxi, 39,  
     40, 278  
 prescribing process, 98–99, 153  
*Prescription Cost Analysis for England 2017* (NHS), 7  
 prescription form safety, 47  
 prescription only medicines (POM), 38, 61  
 Prescription Only Medicines (Human Use) Order  
     (1997), 37, 38, 59  
 prescription writing, 53–58  
     guidelines, 55–57, **56**  
     Latin abbreviations, **57**, 57–58  
     prescribing rights, 53–55, **54**  
 presenting complaint, 143  
 pre-surgical assessment, 314  
 previous experience, 109  
 primary care, 6, 126, 189, 228, 275, 291–292  
 primary legislation, 49  
 principle of double effect (PDE), 85  
 principlism, 82  
 private law, 49  
 private sector, 8–9  
 problematic polypharmacy, 288  
 problem-oriented medical record (POMR),  
     130–131  
 product influence on prescribing, 107–109  
 professional attire, 123  
 professional credentials, 102  
 professional frameworks for prescribing, **37**  
 professional indemnity, 41–42  
 professional integrity, 83

- professional issues, 35–47, 86  
 accountability and responsibility, 40–41  
 changes in ethics, legislation and, 35–36  
 evidence-based practice, 43–44  
 fraud, criminal behaviour and whistleblowing, 44–45  
 influence of, on prescribing, 100  
 and medicines legislation, 37–39  
 with prescribing for children and young people, 263–264  
 prescription form safety, 47  
 professional indemnity, 41–42  
 and regulatory framework for prescribing, 36–37  
 remote prescribing, 45–46  
 standards of professional organizations, 39–40  
 transcribing or transposing, 46–47  
 vicarious liability, 42–43
- professional organizations, standards of, 39–40
- progestogens, 255
- proprietary name prescribing, 166, 179
- prostaglandins, 159
- protein binding, 157–158
- proton pump inhibitors (PPIs), 290
- psychological framework, for CDM, 146
- psychotropics, 257
- public health  
 and clinical practice, 6  
 clinical skills related to, 234  
 and consultation umbrella model, 147  
 as context for NMP, 9–11  
 current UK health policy, 9–10  
 enhancing NMP in, 303  
 and group-specific prescribing, 269  
 influence of, on prescribing, 113  
 for MDPTs, 203  
 patient needs and expectations, 10–11  
 in pharmacology, 180  
 professional, legal and ethical issues related to, 86  
 in United Kingdom, 29  
 Public Health England (PHE), 6, 104, 258  
*Public Health Outcomes Framework 2016-2019* (PHE), 6  
 public law, 49  
 pulse, **218**  
 pulse oximetry, **214**, 214–215  
 pulse rate, 217–218  
 pyrexia, 220
- Quality, Innovation, Prevention, and Productivity (QIPP) agenda, 284
- quality-of-life criterion, 84
- quinine, 231
- radial artery, 217
- radiographers, xviii, 17, 24–25, 191–192, 320
- radiopharmaceuticals, 253
- radiotherapy radiographers, 192
- rapport, with children, 264
- reasoned action, theory of, 105, 106
- receptors, 160–162, 161
- rectal temperature monitoring, 220
- red flags, in clinical examinations, 228
- Reference Guide to Consent for Examination or Treatment, 64
- reflection on prescribing practice model, 277–280, 278
- reflective practice, 276–280  
 barriers to, 279–280  
 defined, 276–277  
 and EBP/CPD, 297  
 elements of, 278–279  
 models for, 277, 277–279
- regional formularies, 301
- regulatory framework for prescribing, 36–37, **37**
- religion, 104–105
- remote prescribing, 45–46
- remuneration, 96
- Renal Database, 245
- renal disease, 245–248, **248**
- renal function, 159, 244–245, 256
- renal impairment, 170, 171, 244–248, 247  
 and adverse drug reactions, 175  
 assessment of renal function, 244–245  
 holistic approach to prescribing with, 247–248  
 pharmacodynamics in, 246–247  
 pharmacokinetics in, 245–246
- repeat prescriptions, 99, 258
- representativeness, 144
- research and development costs, 110–111
- resource factors in prescribing, 96–98
- respect, 82–83
- respiratory rate, 212–213, **213**
- respiratory system, examining, 228, **229–230**
- responsibility, 40–41
- Review of Prescribing, Supply, and Administration of Medicines* (DH), 11, 14
- Review of Prescribing and Administration of Medicines: Final Report* (DH),  
 see *Crown Report II*
- Rinne test, 231
- risk assessment, 79–80, 259
- risk reduction, 140

- route of administration, 156, 253, 260
- Royal College of Nursing (RCN), 42, 66, 197
- Royal College of Physicians (RCP), 210
- Royal Pharmaceutical Society (RPS), 7, 13, 40, 101, 111. *see also A Competency Framework for all Prescribers*
- Royal Sussex Hospital, 44
- rule of double effect (RDE), 85
- safeguarding, 265
- safety
  - concordance building for, 293–296
  - in consultation umbrella model, 117, 118
  - culture of, 97
  - drug safety profile, 254
  - and heuristics/intuition, 145
  - and medicines optimisation, 284
  - and pattern recognition, 144
  - in prescribing, 5
  - prescription form, 47
- Salmond test, 42
- Saving Lives* (DH), 12
- school nurses, 19, 20
- Scotland, 35, 72, 74, 244, 251, 267
- secondary care
  - case studies, 312, 314
  - interface with, 291–292
  - NMP activity in, 6, 275
  - pharmacist prescribing in, 189
  - referral to, 314
  - relationships with older people in, 126
- secondary legislation, 49
- sedating antihistamines, 242
- selective serotonin reuptake inhibitor (SSRI), 20
- self-awareness, 276
- self-management, 104
- self-medication, 103
- self-monitoring, by men, 267
- serum creatinine, 245
- shared decision-making, 104, 294
- Shipman, Harold, 44
- sickle cell disease, 267
- Sidaway v Bethlem Royal Hospital Governors*, 67, 68
- side effects, 67, 85, 169, 174, 175, 253
- signs, in clinical examination, 222
- 'Single Competency Framework for all Prescribers' (NPC), xix
- sinuses, examination of, **232–233**
- 6 Cs (core values), 7
- Smith, Dame Janet, 44
- smoking, 258
- SN@P, 299
- social and cultural issues
  - for children and young adult patients, 265
  - clinical skills and sensitivity to, 235
  - in consultation umbrella model, 148
  - and enhancing NMP, 303
  - and group-specific prescribing, 269
  - influence of, on prescribing, 104, 114
  - for male patients, 267
  - in MDPTs, 203
  - in pharmacology, 180
  - professional, legal and ethical issues related to, 86
  - in United Kingdom, 30
- social care services, 6
- social rules, 48
- Society and College of Radiographers, 191
- Society of Chiropractors and Podiatrists, 193
- Society of Radiographers, 25
- specials manufacturers, 262
- speech, inspection of, 224
- spirituality, 104–105
- Standards for Medicines Management (NMC), 46–47
- Standards for Prescribing Programmes (NMC), 2
- 'Standards of proficiency for registered nurses' (NMC), 96, 97, 100
- stats, 282
- stethoscope, 226
- STOPP/START screening tool, 285, 289
- Strategic Health Authority (SHA), 300
- students, 55, 319
- substance use, 264
- summaries of product characteristics (SPCs), 167, 240, 250
- supplementary prescribers and prescribing, 17
  - by allied health professionals, 24
  - case studies, 317–319
  - clinical management plans, 15–16
  - development of, xviii
  - independent prescribing vs, 13
  - by nurses, 189
  - by optometrists, 192
  - partnership principle, 14–15
  - by pharmacists, 17, 22–23, 189
  - resistance to, 17–19
  - termination, 16
  - in United Kingdom, 14–19
- support, for prescribers, 96–97, 281, **281**
- surgical practice, by podiatrists, 193
- sustainability and transformation plans (STPs), 184
- SWOT analysis, 280

- symptom analysis tools, **139**  
 symptoms, in clinical examination, 222  
 systolic pressure, 215
- tachypnoea, 213  
 teams, defining, 183–184  
 teenagers, 264  
 temazepam, 24, 25  
 temperature (body), 220, **221**  
 temporal artery, 218  
 teratogenicity, 248–249  
 termination, CMP, 16, **16**  
 tests, in consultation umbrella model, 139  
 thalassaemia, 267  
 thalidomide, 249  
 theophylline, 179  
 theory of reasoned action/theory of planned  
   behaviour, 105, 106  
 therapeutic communication  
   with children and young people, 126, **127**  
   in consultation umbrella model, 119–126  
   developing relationships with, 123, 125  
   with older people, 126  
   significance of, 118  
 therapeutic drug monitoring (TDM), 179  
 therapeutic index, narrow, 178–179, 259  
 therapeutic radiographers, 24–25, 192, 318  
 therapeutic relationship, 101, 102, **125**  
 thiazides, 255  
 thorax, examination of, 225  
 thyroid gland, examination of, **234**  
 time  
   and adverse drug reactions, 176–177  
   for CPD, 296  
   in prescribing process, 98–99  
   for therapeutic communication, 120–121  
 ‘Toolkit for general practice in supporting  
   older people living with frailty’ (NHS  
   England), 258  
 tort law, 50–53  
 total purchase schemes, 301  
 touch, in inspection, 225  
 traffic light scheme, 295  
 tramadol, 242  
 transcribing, 46–47  
 transposing, 46–47  
 travellers, 268–269  
 treatment regimens, 120  
   for children and young people, 263  
   in consultation umbrella model, 139–140  
   for older people, 258  
 tricyclic antidepressants, 163, 242, 257
- tripod position, 212, 228  
 trust, 97  
 tympanic membrane, examining, 220
- UK Caldicott Guardian Council, 77  
 UK Drugs in Lactation Advisory Service, 254  
 UK Medicines Information (UKMI) Centres, 262  
 unaffected areas, examination of, 223  
 unaware respiratory rate, 212  
 undiagnosed conditions, 13  
 United Kingdom  
   care regulators, **46**  
   cost of prescribed drugs, 301  
   current health policy, 9–10  
   education programme access, 28  
   independent prescribing, 11–14  
   legal system, 48–51  
   non-medical prescribing, 1–30, 274  
   PGD use, 26–28  
   pharmaceutical industry, 109  
   prescriber differentiation, 11–26  
   supplementary prescribing, 14–19  
 unlicensed medicines, 60–61  
 utilitarianism, 82
- V100 prescribing status, xviii, 19–20, 301, 315  
 V150 Community Practitioner Nurse Prescribing  
   (2009), xviii  
 V150 prescribing status, xviii, 20–21, 275,  
   301, 316  
 V200 prescribing status, 21  
 V300 prescribing status, 21–22, 315, 316  
 vasodilators, 257  
 verbal communication, 121, 123  
 verbal consent, 65  
 vicarious liability, 42–43  
 virtue ethics, 82  
 vision, for non-medical prescribing, 3  
 Vistabel®, 9, 46  
 vital signs, 211–222  
   blood pressure, 215–217  
   factors to consider before recording, 210  
   level of consciousness, 219  
   NEWS2, 209–211  
   oxygen saturation, 214–215  
   pain, 220–222  
   peak expiratory flow rate, 213–214  
   pulse rate, 217–218  
   respiratory rate, 212–213  
   temperature, 220, **221**  
 vitamin D, 246  
 vitamin K, 257

voltage-gated ion channels, 162–163  
vulnerability, feelings of, 96

Wales, 35, 72, 74, 251, 267

warfarin, 158, 241, 246, 254, 257, 287

water-soluble drugs, 246, 256, 260

Weber test, 231

welfare attorneys, 74

welfare guardians, 74

whistleblowing, 44–45

women

benefits of breastfeeding for, 253

breastfeeding mothers, 253–255, **255**

health services utilisation by, 266–267

pregnant, 248–252, **249**, 310

*Working Together to Safeguard Children*

(HM Government), 185

World Health Organization (WHO), 174, 210, 210,  
211, 222

written consent, 66

Yellow Card Scheme, 39, 177, 284

young people, 260–266, **266**

case studies, 311

consent from, 72

consultations with, 126

defining, 260

dosing for, 261

excipients for, 262

holistic approach to prescribing for, 264–265

licensing of medicines for, 261–262

pharmacokinetics for, 260–261

professional responsibilities related to

prescribing for, 263–264